Therefore, imaging modalities, such as whole-body magnetic resonance imaging (MRI), prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography (PET/CT), and PSMA–PET/MRI, were introduced for better cancer localization and staging, refining the discrimination between intermediate-risk and high-risk PCa [4–7]. This evidence concerns the gene FOLH1 and cancer.